PMID- 26965932
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20161230
IS  - 1876-7605 (Electronic)
IS  - 1936-8798 (Linking)
VI  - 9
IP  - 5
DP  - 2016 Mar 14
TI  - Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients 
      Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the 
      ZEUS Trial.
PG  - 426-36
LID - S1936-8798(15)01751-3 [pii]
LID - 10.1016/j.jcin.2015.11.015 [doi]
AB  - OBJECTIVES: This study sought to investigate the ischemic and bleeding outcomes 
      of patients fulfilling high bleeding risk (HBR) criteria who were randomized to 
      zotarolimus-eluting Endeavor Sprint stent (E-ZES) or bare-metal stent (BMS) 
      implantation followed by an abbreviated dual antiplatelet therapy (DAPT) duration 
      for stable or unstable coronary artery disease. BACKGROUND: DES instead of BMS 
      use remains controversial in HBR patients, in whom long-term DAPT poses safety 
      concerns. METHODS: The ZEUS (Zotarolimus-Eluting Endeavor Sprint Stent in 
      Uncertain DES Candidates) is a multinational, randomized single-blinded trial 
      that randomized among others, in a stratified manner, 828 patients fulfilling 
      pre-defined clinical or biochemical HBR criteria-including advanced age, 
      indication to oral anticoagulants or other pro-hemorrhagic medications, history 
      of bleeding and known anemia-to receive E-ZES or BMS followed by a 
      protocol-mandated 30-day DAPT regimen. The primary endpoint of the study was the 
      12-month major adverse cardiovascular event rate, consisting of death, myocardial 
      infarction, or target vessel revascularization. RESULTS: Compared with patients 
      without, those with 1 or more HBR criteria had worse outcomes, owing to higher 
      ischemic and bleeding risks. Among HBR patients, major adverse cardiovascular 
      events occurred in 22.6% of the E-ZES and 29% of the BMS patients (hazard ratio: 
      0.75; 95% confidence interval: 0.57 to 0.98; p = 0.033), driven by lower 
      myocardial infarction (3.5% vs. 10.4%; p < 0.001) and target vessel 
      revascularization (5.9% vs. 11.4%; p = 0.005) rates in the E-ZES arm. The 
      composite of definite or probable stent thrombosis was significantly reduced in 
      E-ZES recipients, whereas bleeding events did not differ between stent groups. 
      CONCLUSIONS: Among HBR patients with stable or unstable coronary artery disease, 
      E-ZES implantation provides superior efficacy and safety as compared with 
      conventional BMS. (Zotarolimus-Eluting Endeavor Sprint Stent in Uncertain DES 
      Candidates [ZEUS]; NCT01385319).
CI  - Copyright (c) 2016 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Ariotti, Sara
AU  - Ariotti S
AD  - Swiss Cardiovascular Center Bern, Inselspital, Bern University Hospital, 
      Switzerland; Thoraxcenter, Erasmus MC, Rotterdam, the Netherlands.
FAU - Adamo, Marianna
AU  - Adamo M
AD  - Thoraxcenter, Erasmus MC, Rotterdam, the Netherlands.
FAU - Costa, Francesco
AU  - Costa F
AD  - Thoraxcenter, Erasmus MC, Rotterdam, the Netherlands.
FAU - Patialiakas, Athanasios
AU  - Patialiakas A
AD  - Cardiology Department, Crete Naval Hospital, Crete, Greece.
FAU - Briguori, Carlo
AU  - Briguori C
AD  - Clinica Mediterranea, Napoli, Italy.
FAU - Thury, Attila
AU  - Thury A
AD  - Cardiology Center, Szeged, Hungary.
FAU - Colangelo, Salvatore
AU  - Colangelo S
AD  - Interventional Cardiology, San Giovanni Bosco Hospital, Torino, Italy.
FAU - Campo, Gianluca
AU  - Campo G
AD  - Cardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Cona, 
      Ferrara, Italy.
FAU - Tebaldi, Matteo
AU  - Tebaldi M
AD  - Cardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Cona, 
      Ferrara, Italy.
FAU - Ungi, Imre
AU  - Ungi I
AD  - Cardiology Center, Szeged, Hungary.
FAU - Tondi, Stefano
AU  - Tondi S
AD  - Azienda Unita Sanitaria Locale di Modena-Ospedale Baggiovara, Italy.
FAU - Roffi, Marco
AU  - Roffi M
AD  - Division of Cardiology, University Hospital, Geneva, Switzerland.
FAU - Menozzi, Alberto
AU  - Menozzi A
AD  - Interventional Cardiology Unit, Azienda Ospedaliero-Universitaria di Parma, 
      Italy.
FAU - de Cesare, Nicoletta
AU  - de Cesare N
AD  - Policlinico S. Marco, Zingonia (Bergamo), Italy.
FAU - Garbo, Roberto
AU  - Garbo R
AD  - Interventional Cardiology, San Giovanni Bosco Hospital, Torino, Italy.
FAU - Meliga, Emanuele
AU  - Meliga E
AD  - Azienda Ospedaliera Ordine Mauriziano, Torino, Italy.
FAU - Testa, Luca
AU  - Testa L
AD  - Interventional Cardiology, Ist. Clinico S. Ambrogio, IRCCS San Donato, Milan, 
      Italy.
FAU - Gabriel, Henrique Mesquita
AU  - Gabriel HM
AD  - Hospital de Santa Cruz, Carnaxide, Lisbon, Portugal.
FAU - Ferlini, Marco
AU  - Ferlini M
AD  - Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
FAU - Vranckx, Pascal
AU  - Vranckx P
AD  - Virga Jesse Ziekenhuis, Hasselt, Belgium.
FAU - Valgimigli, Marco
AU  - Valgimigli M
AD  - Swiss Cardiovascular Center Bern, Inselspital, Bern University Hospital, 
      Switzerland; Thoraxcenter, Erasmus MC, Rotterdam, the Netherlands. Electronic 
      address: marco.valgimigli@insel.ch.
CN  - ZEUS Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT01385319
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - JACC Cardiovasc Interv
JT  - JACC. Cardiovascular interventions
JID - 101467004
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Metals)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - H4GXR80IZE (zotarolimus)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
CIN - JACC Cardiovasc Interv. 2016 Mar 14;9(5):437-9. doi: 10.1016/j.jcin.2015.12.277. 
      PMID: 26965933
MH  - Aged
MH  - Aged, 80 and over
MH  - Cardiovascular Agents/administration & dosage
MH  - Coronary Artery Disease/diagnostic imaging/mortality/*therapy
MH  - Drug Therapy, Combination
MH  - Drug-Eluting Stents
MH  - Female
MH  - Hemorrhage/*chemically induced/mortality
MH  - Humans
MH  - Male
MH  - *Metals
MH  - Myocardial Infarction/etiology
MH  - Patient Selection
MH  - Percutaneous Coronary Intervention/adverse effects/*instrumentation/mortality
MH  - Platelet Aggregation Inhibitors/*adverse effects
MH  - Prosthesis Design
MH  - Risk Assessment
MH  - Risk Factors
MH  - Single-Blind Method
MH  - Sirolimus/administration & dosage/analogs & derivatives
MH  - *Stents
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - dual antiplatelet therapy
OT  - high bleeding risk
OT  - zotarolimus-eluting stent(s)
EDAT- 2016/03/12 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/03/12 06:00
PHST- 2015/05/18 00:00 [received]
PHST- 2015/10/19 00:00 [revised]
PHST- 2015/11/05 00:00 [accepted]
PHST- 2016/03/12 06:00 [entrez]
PHST- 2016/03/12 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - S1936-8798(15)01751-3 [pii]
AID - 10.1016/j.jcin.2015.11.015 [doi]
PST - ppublish
SO  - JACC Cardiovasc Interv. 2016 Mar 14;9(5):426-36. doi: 10.1016/j.jcin.2015.11.015.